1005 ET - Regenerative stem cell-based therapies are poised for a breakthrough as the potential for approvals looks set to thrive in a more favorable regulatory environment, says Maxim Group's Jason McCarthy in a research note. The analyst says such therapies came onto the scene in the mid-2010s and contracted shortly afterwards, but can now step back into the limelight. McCarthy notes that two companies that have benefited from recent changes are Mesoblast and Capricor Therapeutics, with valuations of both rising significantly this year. He adds that RFK Jr., Trump's pick to run the Department of Health and Human Services, seems enthusiastic about stem cell research despite criticizing vaccines and fluoride. (denny.jacob@wsj.com; @pennedbyden)
(END) Dow Jones Newswires
December 12, 2024 10:05 ET (15:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.